IFNG and neoplasm: An ongoing clinical study (NCT04725474) demonstrated that the GDF-15 neutralizing antibody visugromab combined with nivolumab can overcome immunotherapy resistance in NSCLC patients, enhancing IFN-γ signaling within the tumor microenvironment and promoting GZMB+ CD8+ T cell infiltration (130).